NTHI
NeOnc Technologies Holdings, Inc. Common StockNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$138.91M
P/E Ratio
—
EPS
$-1.80
Beta
—
52W High
$12.99
52W Low
$3.20
50-Day MA
$5.88
200-Day MA
$8.25
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NeOnc Technologies Holdings, Inc. Common Stock
NeOnc Technologies Holdings, Inc. is an innovative biotechnology company focused on transforming cancer care through cutting-edge immunotherapy and molecular medicine. The firm's robust pipeline features several advanced product candidates addressing significant unmet needs in oncology, positioning it to lead in reshaping treatment approaches and improving patient outcomes. With strategic collaborations across the biopharmaceutical landscape, NeOnc is well-equipped to expedite the commercialization of its therapeutic innovations, making it a noteworthy opportunity for institutional investors looking to capitalize on growth in the cancer therapeutics market.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | — |
| Operating Margin | 0.00% |
| Return on Equity | 0.00% |
| Return on Assets | -354.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $-0.80 |
| Price-to-Book | — |
| Price-to-Sales (TTM) | 3477.63 |
| EV/Revenue | 3684.63 |
| EV/EBITDA | — |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $26.01M |
| Float | $7.99M |
| % Insiders | 56.04% |
| % Institutions | 11.25% |
Historical Volatility
HV 10-Day
24.95%
HV 20-Day
128.94%
HV 30-Day
109.08%
HV 60-Day
94.93%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($16.00 target)
1
BuyMore HEALTHCARE Stocks
Data last updated: 5/25/2026